Clinical trial NCT02840474: Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
Official title: VRC 607-ACTG A5378: A Phase 1, Single Dose Study of the Safety and Virologic Effect of an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS) or VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously to HIV-Infected Adults.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HIV-1
Keywords: HIV Viral Load
Antiviral
CD4 Count
HIV-1 Infection
Broadly Neutralizing Antibody
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
Collaborators: name: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
First posted: 2016-07-21
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Background:

The human body uses antibodies as one way to help fight infection. VRC01LS and VRC07-523LS are antibodies directed against the HIV virus. Researchers want to see if they are safe and well tolerated. In Part A of the study, the researchers studied VRC01LS. Part A of the study was completed in 2017. In Part B, the researchers studied VRC07-523LS. Depending on which antibody received, researchers studied the amount of VRC01LS or VRC07-523LS in the body and how it changes over time. They evaluated the effect of antibodies on CD4+ (Cluster of Differentiation 4) lymphocyte count and HIV viral load, and checked to see if people who get VRC01LS or VRC07-523LS develop an immune response to it.

Objective:

To see if VRC01LS and VRC07-523LS are safe and well tolerated.

Eligibility:

Adults ages 18-70 who are HIV infected but otherwise healthy.

Design:

Participants received the study drug one time by IV infusion. A needle guided a thin tube into a vein. The study drug mixed with salt water was dripped into the vein over about 30 minutes.

Participants were monitored for 30 minutes after the infusion.

Blood samples were taken at the following times:

* Once before the infusion
* 5 times in the 4 hours after the infusion
* 1 time 24 hours after infusion. Some participants may have had 3 optional blood draws in the time period between 4 and 24 hours.

For 3 days after the infusion, participants recorded their temperature and reactogenicity symptoms in a diary.

There were a total of 23 study visits over 48 weeks. Ten visits were in the first 4 weeks. At all visits, participants answered health questions and gave blood samples.

Detailed description: Study Design:

Open-label, single dose study to examine safety, tolerability, pharmacokinetics and virologic impact of VRC01LS or VRC07-523LS in HIV-infected viremic adults.

Study Hypotheses:

This is the first study of VRC01LS or VRC07-523LS in HIV-infected viremic adults. The primary hypothesis is that both VRC01LS and VRC07-523LS will be safe for intravenous administration to HIV-1-infected adults. The secondary hypothesis is that VRC01LS and VRC07-523LS will be detectable in human sera with a definable half-life.

Product Description:

VRC-HIVMAB080-00-AB (VRC01LS) and VRC-HIVMAB075-00-AB (VRC07-523LS) are human monoclonal antibodies (MAbs) targeted to the CD4+ binding site of HIV-1. Both MAbs are modifications of the VRC01 MAb (which has been shown to be safe and to have antiviral activity in human studies) with the addition of the "LS", a 2-amino acid mutation designed to improve the half-life of the antibody. These MAbs were developed and manufactured by VRC/NIAID/NIH under current Good Manufacturing Practice (cGMP) at the VRC Vaccine Pilot Plant operated under contract by the Vaccine Clinical Materials Program (VCMP), Leidos Biomedical Research, Inc., Frederick, MD. Vials were provided at 100 mg/mL.

Participants:

HIV-1-infected viremic adults; 18-70 years of age.

Study Plan:

This study assessed VRC01LS or VRC07-523LS administered at 40 mg/kg IV in HIV-infected viremic participants. Participants enrolled in one of two parts: Part A (VRC01LS) or Part B (VRC07-523LS). A total of 7 participants were enrolled in Part A and received VRC01LS and a total of 9 participants were enrolled in Part B and received VRC07-523LS. Safety lab samples, HIV viral load, CD4+ lymphocyte count, pharmacokinetic (PK) samples, and blood samples for detection of human anti-VRC01LS antibody (Part A) and human anti-VRC07-523LS antibody (Part B) were drawn at baseline and intervals throughout the study. Participants recorded in a daily diary reactogenicity symptoms for 3 days after study product administration and were queried at each study visit for adverse events. Participants were strongly encouraged to initiate 3-drug anti-retroviral therapy (ART), prescribed by their primary HIV clinician; not study-provided, any time after completing the day 14 study evaluations.

VRC 607/A5378 Study Schema:

* Part: A; Participants: 7; Product: VRC01LS; Administration Schedule (Day 0): 40 mg/kg IV.
* Part: B; Participants: 9; Product: VRC07-523LS; Administration Schedule (Day 0): 40 mg/kg IV.

  * Total Participants: 16

Study Duration:

Participants were followed for 48 weeks after study product administration.

Eligibility criteria: INCLUSION CRITERIA:

A participant must meet all of the following criteria:

1. Able and willing to complete the informed consent process.
2. 18-70 years old
3. Available for clinic visits for 48 weeks after study product administration.
4. HIV-1 infected and clinically stable. \[Note: Documented HIV-1 infection by HIV enzyme immunoassay (EIA) performed by a Clinical Laboratory Improvement Amendments (CLIA) certified outside lab within 28 days of enrollment is acceptable.\]
5. At least one plasma viral load \>=500 copies/mL within 28 days of enrollment. A plasma viral load within 28 days and closest to the day of enrollment, that is detectable but not greater than 100,000 copies/mL. \[Note: outside laboratory results will be acceptable\].
6. A CD4+ count \>=350 cells/microliter (mcL) on 2 of 3 consecutive testing occasions (or on 2 of 2 sequential tests) within 28 days prior to enrollment. \[Note: outside laboratory results will be acceptable\].
7. In general good health as assessed by a study clinician and under the care of a primary health care provider for medical management of HIV infection while participating in the study. Willing to give consent to contact and send laboratory results to the participant's primary health provider.
8. Willing to have blood samples collected, stored indefinitely, and used for various research purposes.
9. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
10. Screening laboratory values within 28 days prior to enrollment must meet the following criteria:

    * Absolute neutrophil count \>=800/mcL
    * Platelets \>=100,000/mcL
    * Hemoglobin \>=10.0 g/dL
    * Creatinine less than or equal to 1.31 mg/dL
    * Alanine aminotransferase (ALT) less than or equal to 2.5 x upper limit of normal (ULN)
    * Negative Hepatitis B Surface Antigen (HBsAg)
    * Undetectable Hepatitis C Viral Load (HCV RNA)

    \[Note: Documented negative HBsAg and HCV RNA performed by an outside CLIA certified lab within 28 days of enrollment are acceptable.\]

    Female-Specific Criteria:
11. If a woman is sexually active with a male partner and has no history of hysterectomy, tubal ligation, or menopause, she must agree to use either a prescription birth control method or a barrier birth control method from the time of study enrollment until the last study visit, or have a monogamous partner who has had a vasectomy.
12. Negative beta-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day of enrollment for women presumed to be of reproductive potential.

EXCLUSION CRITERIA:

A participant will be excluded if one or more of the following conditions apply:

1. Previous receipt of humanized or human monoclonal antibody whether licensed or investigational.
2. Prior use of antiretroviral therapy.
3. Ongoing AIDS-related opportunistic infection (including oral thrush).
4. Active drug or alcohol use or dependence in the opinion of the site investigator that would interfere with adherence to study requirements.
5. Any history of a severe allergic reaction, including generalized urticaria, angioedema or anaphylaxis prior to enrollment, that has a reasonable risk of recurrence during the study.
6. Physical finding on examination considered clinically significant.
7. Hypertension that is not well controlled.
8. Weight \>115 kg (253 pounds).
9. Breast-feeding.
10. Receipt of any investigational study product within 28 days prior to enrollment.
11. Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer.

Primary outcomes:
measure: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration
timeFrame: 3 days after study product administration
measure: Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration
timeFrame: 3 days after study product administration
measure: Number of Participants With Abnormal Laboratory Measures of Safety
timeFrame: Through 48 weeks after study product administration
measure: Number of Participants With One or More Unsolicited Non-Serious Adverse Events (AEs)
timeFrame: Through 56 days after study product administration
measure: Number of Participants With Serious Adverse Events (SAEs)
timeFrame: Through 48 weeks after study product administration
Secondary outcomes:
measure: Area Under the Curve For the Last Study Visit (AUC(Last))
timeFrame: Administration (0h) to 48 weeks after study product administration
measure: Clearance Rate of VRC01LS or VRC07-523LS Administered at 40 mg/kg IV
timeFrame: Administration (0h) to 48 weeks after study product administration
measure: Maximum Observed Serum Concentration (Cmax) of VRC01LS or VRC07-523LS Administered at 40 mg/kg IV
timeFrame: Through 48 weeks after study product administration
measure: Half-life (T1/2) of VRC01LS or VRC07-523LS Administered at 40 mg/kg IV
timeFrame: Through 48 weeks after study product administration
measure: Mean Serum Concentration of VRC01LS or VRC07-523LS Administered at 40 mg/kg IV
timeFrame: Day 28 and Day 84 after study product administration
measure: Time to Reach Maximum Observed Serum Concentration (Tmax) of VRC01LS or VRC07-523LS Administered at 40 mg/kg IV
timeFrame: Through 48 weeks after study product administration
measure: Number of Participants Who Produced Anti-drug Antibodies to VRC01LS or VRC07-523LS Administered at 40 mg/kg IV
timeFrame: Day 28 and Day 56 after study product administration
measure: Log10 Change in Viral Load (VL) From Baseline to Nadir (Lowest Detectable Value) Prior to Antiretroviral Therapy (ART) Initiation
timeFrame: Baseline through 48 weeks after study product administration
measure: Day of Nadir (Lowest Detectable) VL Prior to ART Initiation
timeFrame: Baseline through 48 weeks after study product administration
measure: Overall Change in CD4+ Lymphocyte Count From Baseline to Peak Prior to ART Initiation
timeFrame: Baseline through 48 weeks after study product administration
measure: Day of Peak CD4+ Lymphocyte Count Prior to ART Initiation
timeFrame: Baseline through 48 weeks after study product administration
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama HIV Clinic Clinical Research Site, AIDS Clinical Trials Group (ACTG)
state: Alabama
city: Los Angeles
country: United States
facility: UCLA CARE Center, AIDS Clinical Trials Group (ACTG)
state: California
city: Saint Louis
country: United States
facility: Washington University Therapeutics, AIDS Clinical Trials Group (ACTG)
state: Missouri
city: Cincinnati
country: United States
facility: University of Cincinnati University Hospital, AIDS Clinical Trials Group (ACTG)
state: Ohio
city: Columbus
country: United States
facility: Ohio State University Clinical Research Site, AIDS Clinical Trials Group (ACTG)
state: Ohio
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania Clinical Research Site, AIDS Clinical Trials Group (ACTG)
state: Pennsylvania
city: San Juan
country: Puerto Rico
facility: Puerto Rico AIDS Clinical Trials Unit, AIDS Clinical Trials Group (ACTG)
Study officials:
affiliation: National Institute of Allergy and Infectious Diseases (NIAID)
name: Martin R Gaudinski, M.D.
role: STUDY_CHAIR
References:
citation: Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, Hendel CS, Pegu A, Conan-Cibotti M, Sitar S, Bailer RT, Narpala S, McDermott A, Louder M, O'Dell S, Mohan S, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Mascola JR, Graham BS; VRC 602 Study Team. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015 Dec;182(3):289-301. doi: 10.1111/cei.12692. Epub 2015 Sep 24.
citation: Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O'Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE; VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015 Dec 23;7(319):319ra206. doi: 10.1126/scitranslmed.aad5752.
citation: Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, Wang K, Bao S, Kraemer TD, Rath T, Zeng M, Schmidt SD, Todd JP, Penzak SR, Saunders KO, Nason MC, Haase AT, Rao SS, Blumberg RS, Mascola JR, Nabel GJ. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014 Oct 30;514(7524):642-5. doi: 10.1038/nature13612. Epub 2014 Aug 13.